Acitretin may improve symptoms and exudation in patients affected by elephantiasis nostras verrucosa: Report of a case.
We report the case of a 63-year-old Italian woman who had been permanently confined to a wheelchair for 10 years and had a 4-year history of lymphoedema in her legs, including her foot. Verrucous, cobblestone-like lesions gradually developed over the skin in these areas (Figure 1). She reported pain, burning, and heaviness. The clinical picture is exacerbated by the great exudation. Her medical history was relevant for decompensated type 2 diabetes mellitus, chronic renal failure on dialysis, hypertension associated with hypertriglyceridemia, hypercholesterolemia, and severe obesity (body mass index > 35 kg/m2). Her surgical, travel, and family anamnesis was unremarkable. Personal and familial history of filariasis was negative. Histologically, the epidermis showed marked hyperplastic changes, with variable acanthosis, parakeratosis, and mild dysplasia. In the dermis, stromal activation, an increase in small vessels with some red cell extravasation, and moderate chronic inflammatory cell infiltrate were observed (Figure 2A–D). Based on the results of the skin biopsy and personal history, we made a diagnosis of elephantiasis nostras verrucosa (ENV). She refused manual and mechanical massage and compression with elastic bandages or stockings. She declined any surgical intervention. Therefore, she was started on therapy with a low dose of acitretin (20 mg/die) because of her comorbidities. We recommended daily disinfection with sodium hypochlorite solution and foam medication. A suggestion was made to increase ambulation, to elevate her legs, and to reduce her body weight. The clinical examination 2 months after starting therapy with acitretin showed a substantial clinical improvement; she particularly reported a reduction of symptoms and exudation, and no worsening of serum lipids and liver function were registered. The result of the visual analog scale (VAS) assessment was reduced from 9 (before starting treatment) to 3 (2 months after). Obviously, the choice of the right therapy must take into account patient's comorbidities: our subject had numerous concomitant pathological conditions and refused treatments that included hospital accesses. Therefore, therapy with low-dose acitretin has proven to be helpful in alleviating the symptomatology and exudation of the ENV, and it can be considered in those patients whose management is exclusively domiciliary. ENV comprises a rare skin disease characterised by dermal fibrosis, hyperkeratotic, verrucous, and papillomatous lesions that usually occur after chronic secondary, non-filarial lymphoedema.1 Several causes may be involved, such as obesity, recurrent bacterial infection, radiation, pretibial myxoedema, portal hypertension, tumour, or surgical damage to the lymphatic system. It can appear anywhere, especially on the lower legs and feet, but also rarely on the face, ear, upper extremities, abdomen, and scrotum. ENV presents with a progressive diffuse non-pitting oedema and hyperkeratotic papulo-nodule with a final verrucous and mossy appearance, associated with several degrees of exudation. The diagnosis is usually based on anamnesis, clinical investigations, and skin biopsy. Abnormal findings, such as pseudoepitheliomatous hyperplasia, dilated lymphatic spaces, fibrous tissue hyperplasia, and chronic inflammation, are reported. No standard treatments exist, and data obtained by literature are very less. The main target of any therapy should be the reduction of the lymphoedema and exudation. Manual and mechanical massage and compression with elastic bandages or stockings have been described to be beneficial.2 Some authors reported the effectiveness of external sequential pneumatic compression devices.3 Weight reduction may help achieve better and faster improvement. In addition, antibiotic prophylaxis could be important based on antibiogram result. Oral or topical retinoids should be considered an adjunct to physiotherapy. They play a key role in keratinocyte proliferation; in the induction of collagen degradation; and in fibrosis, inflammation, and exudation. In some cases, the cutaneous signs recurred under retinoid therapy probably because they improve cutaneous changes but do not resolve the causes of lymphoedema.4 For cases that have not responded well to conservative or medical treatment, surgical intervention and/or debridement should be attempted.5 Surgical therapy can be considered an alternative treatment in advanced or refractory cases to previous therapies. None declared. The authors have no conflicts of interest to report.
Read more